Advertisement

Radiotherapy for recurrent prostate cancer: 2018 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group

      Abstract

      The management of patients with biochemical, local, nodal, or oligometastatic relapsed prostate cancer has become more challenging and controversial. Novel imaging modalities designed to detect recurrence are increasingly used, particularly PSMA-PET scans in Australia, New Zealand and some European countries. Imaging techniques such as MRI and PET scans using other prostate cancer-specific tracers are also being utilised across the world. The optimal timing for commencing salvage treatment, and the role of local and/or systemic therapies remains controversial. Through surveys of the membership, the Australian and New Zealand Faculty of Radiation Oncology Genito-Urinary Group (FROGG) identified wide variation in the management of recurrent prostate cancer. Following a workshop conducted in April 2017, the FROGG management committee reviewed the literature and developed a set of recommendations based on available evidence and expert opinion, for the appropriate investigation and management of recurrent prostate cancer. These recommendations cover the role and timing of post-prostatectomy radiotherapy, the management of regional nodal metastases and oligometastases, as well as the management of local prostate recurrence after definitive radiotherapy.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Radiotherapy and Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Tendulkar R.D.
        • Agrawal S.
        • Gao T.
        • Efstathiou J.A.
        • Pisansky T.M.
        • Michalski J.M.
        • et al.
        Contemporary update of a multi-institutional predictive nomogram for salvage radiotherapy after radical prostatectomy.
        J Clin Oncol. 2016; 34: 3648-3654
        • Carrie C.
        • Hasbini A.
        • de Laroche G.
        • Richaud P.
        • Guerif S.
        • Latorzeff I.
        • et al.
        Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.
        Lancet Oncol. 2016; 17: 747-756
        • Shipley W.U.
        • Seiferheld W.
        • Lukka H.R.
        • Major P.P.
        • Heney N.M.
        • Grignon D.J.
        • et al.
        Radiation with or without antiandrogen therapy in recurrent prostate cancer.
        N Engl J Med. 2017; 376: 417-428
        • Sweeney C.J.
        • Chen Y.H.
        • Carducci M.
        • Liu G.
        • Jarrard D.F.
        • Eisenberger M.
        • et al.
        Chemohormonal therapy in metastatic hormone-sensitive prostate cancer.
        N Engl J Med. 2015; 373: 737-746
        • James N.D.
        • Sydes M.R.
        • Clarke N.W.
        • Mason M.D.
        • Dearnaley D.P.
        • Spears M.R.
        • et al.
        Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
        Lancet. 2016; 387: 1163-1177
        • Fizazi K.
        • Tran N.
        • Fein L.
        • Matsubara N.
        • Rodriguez-Antolin A.
        • Alekseev B.Y.
        • et al.
        Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer.
        N Engl J Med. 2017; 377: 352-360
      1. Oxford Centre for Evidence-based Medicine – Levels of Evidence; March 2009.

        • Thompson I.M.
        • Valicenti R.K.
        • Albertsen P.
        • Davis B.J.
        • Goldenberg S.L.
        • Hahn C.
        • et al.
        Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline.
        J Urol. 2013; 190: 441-449
      2. RTOG 0534. Prostate radiation therapy or short-term androgen deprivation therapy and pelvic lymph node radiation therapy with or without prostate radiation therapy in treating patients with a rising prostate specific antigen (PSA) after surgery for prostate cancer. Available from: <https://clinicaltrials.gov/ct2/show/record/NCT00567580>.

        • Thompson I.M.
        • Tangen C.M.
        • Paradelo J.
        • Lucia M.S.
        • Miller G.
        • Troyer D.
        • et al.
        Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial.
        J Urol. 2009; 181: 956-962
        • Thompson Jr., I.M.
        • Tangen C.M.
        • Paradelo J.
        • Lucia M.S.
        • Miller G.
        • Troyer D.
        • et al.
        Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial.
        JAMA. 2006; 296: 2329-2335
        • Bolla M.
        • van Poppel H.
        • Tombal B.
        • Vekemans K.
        • Da Pozzo L.
        • de Reijke T.M.
        • et al.
        Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911).
        Lancet. 2012; 380: 2018-2027
        • Bolla M.
        • van Poppel H.
        • Collette L.
        • van Cangh P.
        • Vekemans K.
        • Da Pozzo L.
        • et al.
        Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911).
        Lancet. 2005; 366: 572-578
        • Wiegel T.
        • Bartkowiak D.
        • Bottke D.
        • Bronner C.
        • Steiner U.
        • Siegmann A.
        • et al.
        Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96–02/AUO AP 09/95 trial.
        Eur Urol. 2014; 66: 243-250
        • Wiegel T.
        • Bottke D.
        • Steiner U.
        • Siegmann A.
        • Golz R.
        • Storkel S.
        • et al.
        Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95.
        J Clin Oncol. 2009; 27: 2924-2930
        • Morgan S.C.
        • Waldron T.S.
        • Eapen L.
        • Mayhew L.A.
        • Winquist E.
        • Lukka H.
        • et al.
        Adjuvant radiotherapy following radical prostatectomy for pathologic T3 or margin-positive prostate cancer: a systematic review and meta-analysis.
        Radiother Oncol. 2008; 88: 1-9
        • Arcangeli S.
        • Ramella S.
        • De Bari B.
        • Franco P.
        • Alongi F.
        • D'Angelillo R.M.
        A cast of shadow on adjuvant radiotherapy for prostate cancer: A critical review based on a methodological perspective.
        Crit Rev Oncol Hematol. 2016; 97: 322-327
        • Pearse M.
        • Fraser-Browne C.
        • Davis I.D.
        • Duchesne G.M.
        • Fisher R.
        • Frydenberg M.
        • et al.
        A Phase III trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: background and rationale of the Radiotherapy - Adjuvant Versus Early Salvage (RAVES) trial.
        BJU Int. 2014; 113: 7-12
        • Parker C.
        • Sydes M.R.
        • Catton C.
        • Kynaston H.
        • Logue J.
        • Murphy C.
        • et al.
        Radiotherapy and androgen deprivation in combination after local surgery (RADICALS): a new Medical Research Council/National Cancer Institute of Canada phase III trial of adjuvant treatment after radical prostatectomy.
        BJU Int. 2007; 99: 1376-1379
        • Richaud P.
        • Sargos P.
        • Henriques de Figueiredo B.
        • Latorzeff I.
        • Mongiat-Artus P.
        • Houede N.
        • et al.
        Postoperative radiotherapy of prostate cancer.
        Cancer Radiother. 2010; 14: 500-503
        • Abdollah F.
        • Karnes R.J.
        • Suardi N.
        • Cozzarini C.
        • Gandaglia G.
        • Fossati N.
        • et al.
        Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer.
        J Clin Oncol. 2014; 32: 3939-3947
        • Gandaglia G.
        • Karakiewicz P.I.
        • Briganti A.
        • Trudeau V.
        • Trinh Q.D.
        • Kim S.P.
        • et al.
        Early radiotherapy after radical prostatectomy improves cancer-specific survival only in patients with highly aggressive prostate cancer: validation of recently released criteria.
        Int J Urol. 2015; 22: 89-95
      3. Post-radical prostatectomy nomogram. Memorial Sloan Kettering Cancer Center. Available from: <https://www.mskcc.org/nomograms/prostate/post_op>.

        • Da Pozzo L.F.
        • Cozzarini C.
        • Briganti A.
        • Suardi N.
        • Salonia A.
        • Bertini R.
        • et al.
        Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy.
        Eur Urol. 2009; 55: 1003-1011
        • Briganti A.
        • Karnes R.J.
        • Da Pozzo L.F.
        • Cozzarini C.
        • Capitanio U.
        • Gallina A.
        • et al.
        Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: results of a matched analysis.
        Eur Urol. 2011; 59: 832-840
        • Jegadeesh N.
        • Liu Y.
        • Zhang C.
        • Zhong J.
        • Cassidy R.J.
        • Gillespie T.
        • et al.
        The role of adjuvant radiotherapy in pathologically lymph node-positive prostate cancer.
        Cancer. 2017; 123: 512-520
        • Touijer K.A.
        • Karnes R.J.
        • Passoni N.
        • Sjoberg D.D.
        • Assel M.
        • Fossati N.
        • et al.
        Survival outcomes of men with lymph node-positive prostate cancer after radical prostatectomy: a comparative analysis of different postoperative management strategies.
        Eur Urol. 2017;
        • Messing E.M.
        • Manola J.
        • Sarosdy M.
        • Wilding G.
        • Crawford E.D.
        • Trump D.
        Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer.
        N Engl J Med. 1999; 341: 1781-1788
        • Messing E.M.
        • Manola J.
        • Yao J.
        • Kiernan M.
        • Crawford D.
        • Wilding G.
        • et al.
        Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy.
        Lancet Oncol. 2006; 7: 472-479
        • Beresford M.J.
        • Gillatt D.
        • Benson R.J.
        • Ajithkumar T.
        A systematic review of the role of imaging before salvage radiotherapy for post-prostatectomy biochemical recurrence.
        Clin Oncol. 2010; 22: 46-55
        • Kane C.J.
        • Amling C.L.
        • Johnstone P.A.
        • Pak N.
        • Lance R.S.
        • Thrasher J.B.
        • et al.
        Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy.
        Urology. 2003; 61: 607-611
        • Cornford P.
        • Bellmunt J.
        • Bolla M.
        • Briers E.
        • De Santis M.
        • Gross T.
        • et al.
        Guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer.
        Eur Urol. 2017; 71: 630-642
        • Valicenti R.K.
        • Thompson Jr., I.
        • Albertsen P.
        • Davis B.J.
        • Goldenberg S.L.
        • Wolf J.S.
        • et al.
        Adjuvant and salvage radiation therapy after prostatectomy: American Society for Radiation Oncology/American Urological Association guidelines.
        Int J Radiat Oncol Biol Phys. 2013; 86: 822-828
        • Evans J.D.
        • Jethwa K.R.
        • Ost P.
        • Williams S.
        • Kwon E.D.
        • Lowe V.J.
        • et al.
        Prostate cancer-specific PET radiotracers: a review on the clinical utility in recurrent disease.
        Pract Radiat Oncol. 2018; 8: 28-39
        • Perera M.
        • Papa N.
        • Christidis D.
        • Wetherell D.
        • Hofman M.S.
        • Murphy D.G.
        • et al.
        Sensitivity, specificity, and predictors of positive 68Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis.
        Eur Urol. 2016; 70: 926-937
        • von Eyben F.E.
        • Picchio M.
        • von Eyben R.
        • Rhee H.
        • Bauman G.
        68Ga-labeled prostate-specific membrane antigen ligand positron emission tomography/computed tomography for prostate cancer: a systematic review and meta-analysis.
        Eur Urol Focus. 2016; (in press)https://doi.org/10.1016/j.euf.2016.11.002
        • van Leeuwen P.J.
        • Stricker P.
        • Hruby G.
        • Kneebone A.
        • Ting F.
        • Thompson B.
        • et al.
        (68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment.
        BJU Int. 2016; 117: 732-739
        • Meredith G.
        • Wong D.
        • Yaxley J.
        • Coughlin G.
        • Thompson L.
        • Kua B.
        • et al.
        The use of 68 Ga-PSMA PET CT in men with biochemical recurrence after definitive treatment of acinar prostate cancer.
        BJU Int. 2016; 118: 49-55
        • Fanti S.
        • Minozzi S.
        • Morigi J.J.
        • Giesel F.
        • Ceci F.
        • Uprimny C.
        • et al.
        Development of standardized image interpretation for 68Ga-PSMA PET/CT to detect prostate cancer recurrent lesions.
        Eur J Nucl Med Mol Imaging. 2017; 44: 1622-1635
        • Wright Jr., G.L.
        • Haley C.
        • Beckett M.L.
        • Schellhammer P.F.
        Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues.
        Urol Oncol. 1995; 1: 18-28
        • Kinoshita Y.
        • Kuratsukuri K.
        • Landas S.
        • Imaida K.
        • Rovito Jr., P.M.
        • Wang C.Y.
        • et al.
        Expression of prostate-specific membrane antigen in normal and malignant human tissues.
        World J Surg. 2006; 30: 628-636
        • Krohn T.
        • Verburg F.A.
        • Pufe T.
        • Neuhuber W.
        • Vogg A.
        • Heinzel A.
        • et al.
        [(68)Ga]PSMA-HBED uptake mimicking lymph node metastasis in coeliac ganglia: an important pitfall in clinical practice.
        Eur J Nucl Med Mol Imaging. 2015; 42: 210-214
        • Artigas C.
        • Alexiou J.
        • Garcia C.
        • Wimana Z.
        • Otte F.X.
        • Gil T.
        • et al.
        Paget bone disease demonstrated on (68)Ga-PSMA ligand PET/CT.
        Eur J Nucl Med Mol Imaging. 2016; 43: 195-196
        • Wright Jr., G.L.
        • Grob B.M.
        • Haley C.
        • Grossman K.
        • Newhall K.
        • Petrylak D.
        • et al.
        Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy.
        Urology. 1996; 48: 326-334
        • Hope T.A.
        • Truillet C.
        • Ehman E.C.
        • Afshar-Oromieh A.
        • Aggarwal R.
        • Ryan C.J.
        • et al.
        68Ga-PSMA-11 PET imaging of response to androgen receptor inhibition: first human experience.
        J Nucl Med. 2017; 58: 81-84
        • King C.R.
        The timing of salvage radiotherapy after radical prostatectomy: a systematic review.
        Int J Radiat Oncol Biol Phys. 2012; 84: 104-111
        • Ohri N.
        • Dicker A.P.
        • Trabulsi E.J.
        • Showalter T.N.
        Can early implementation of salvage radiotherapy for prostate cancer improve the therapeutic ratio? A systematic review and regression meta-analysis with radiobiological modelling.
        Eur J Cancer. 2012; 48: 837-844
        • Stephenson A.J.
        • Scardino P.T.
        • Kattan M.W.
        • Pisansky T.M.
        • Slawin K.M.
        • Klein E.A.
        • et al.
        Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy.
        J Clin Oncol. 2007; 25: 2035-2041
        • Emmett L.
        • Van Leeuwen P.
        • Nandurkar R.
        • Scheltema M.J.
        • Cusick T.
        • Hruby G.
        • et al.
        Treatment outcomes from 68GaPSMA PET CT informed salvage radiation treatment in men with rising PSA following radical prostatectomy: Prognostic value of a negative PSMA PET.
        J Nucl Med. 2017; 58: 1972-1976
        • Kitajima K.
        • Hartman R.P.
        • Froemming A.T.
        • Hagen C.E.
        • Takahashi N.
        • Kawashima A.
        Detection of local recurrence of prostate cancer after radical prostatectomy using endorectal coil MRI at 3 T: addition of DWI and dynamic contrast enhancement to T2-weighted MRI.
        AJR Am J Roentgenol. 2015; 205: 807-816
        • Trock B.J.
        • Han M.
        • Freedland S.J.
        • Humphreys E.B.
        • DeWeese T.L.
        • Partin A.W.
        • et al.
        Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy.
        JAMA. 2008; 299: 2760-2769
        • Stephenson A.J.
        • Shariat S.F.
        • Zelefsky M.J.
        • Kattan M.W.
        • Butler E.B.
        • Teh B.S.
        • et al.
        Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.
        JAMA. 2004; 291: 1325-1332
        • Stish B.J.
        • Pisansky T.M.
        • Harmsen W.S.
        • Davis B.J.
        • Tzou K.S.
        • Choo R.
        • et al.
        Improved metastasis-free and survival outcomes with early salvage radiotherapy in men with detectable prostate-specific antigen after prostatectomy for prostate cancer.
        J Clin Oncol. 2016; 34: 3864-3871
        • Shinghal R.
        • Yemoto C.
        • McNeal J.E.
        • Brooks J.D.
        Biochemical recurrence without PSA progression characterizes a subset of patients after radical prostatectomy. Prostate-specific antigen.
        Urology. 2003; 61: 380-385
        • Fossati N.
        • Karnes R.J.
        • Cozzarini C.
        • Fiorino C.
        • Gandaglia G.
        • Joniau S.
        • et al.
        Assessing the optimal timing for early salvage radiation therapy in patients with prostate-specific antigen rise after radical prostatectomy.
        Eur Urol. 2016; 69: 728-733
        • King C.R.
        The dose–response of salvage radiotherapy following radical prostatectomy: a systematic review and meta-analysis.
        Radiother Oncol. 2016; 121: 199-203
        • Ghadjar P.
        • Hayoz S.
        • Bernhard J.
        • Zwahlen D.R.
        • Holscher T.
        • Gut P.
        • et al.
        Acute toxicity and quality of life after dose-intensified salvage radiation therapy for biochemically recurrent prostate cancer after prostatectomy: first results of the randomized trial SAKK 09/10.
        J Clin Oncol. 2015; 33: 4158-4166
        • Byrne K.
        • Eade T.
        • Kneebone A.
        • Guo L.
        • Hsiao E.
        • Schembri G.
        • et al.
        Delineating sites of failure following post-prostatectomy radiation treatment using (68)Ga-PSMA-PET.
        Radiother Oncol. 2017; 126: 244-248
        • Spiotto M.T.
        • Hancock S.L.
        • King C.R.
        Radiotherapy after prostatectomy: improved biochemical relapse-free survival with whole pelvic compared with prostate bed only for high-risk patients.
        Int J Radiat Oncol Biol Phys. 2007; 69: 54-61
        • Moghanaki D.
        • Koontz B.F.
        • Karlin J.D.
        • Wan W.
        • Mukhopadhay N.
        • Hagan M.P.
        • et al.
        Elective irradiation of pelvic lymph nodes during postprostatectomy salvage radiotherapy.
        Cancer. 2013; 119: 52-60
        • Song C.
        • Kang H.C.
        • Kim J.S.
        • Eom K.Y.
        • Kim I.A.
        • Chung J.B.
        • et al.
        Elective pelvic versus prostate bed-only salvage radiotherapy following radical prostatectomy: a propensity score-matched analysis.
        Strahlenther Onkol. 2015; 191: 801-809
        • Ramey S.J.
        • Agrawal S.
        • Abramowitz M.C.
        • Moghanaki D.
        • Pisansky T.M.
        • Efstathiou J.A.
        • et al.
        Multi-institutional evaluation of elective nodal irradiation and/or androgen deprivation therapy with postprostatectomy salvage radiotherapy for prostate cancer.
        Eur Urol. 2018; (in press)https://doi.org/10.1016/j. eururo.2017.10.009
        • Spratt D.E.
        • Dess R.T.
        • Zumsteg Z.S.
        • Lin D.W.
        • Tran P.T.
        • Morgan T.M.
        • et al.
        A systematic review and framework for the use of hormone therapy with salvage radiation therapy for recurrent prostate cancer.
        Eur Urol. 2018; 73: 156-165
        • Lawton C.A.
        • Winter K.
        • Grignon D.
        • Pilepich M.V.
        Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85–31.
        J Clin Oncol. 2005; 23: 800-807
        • Fossa S.D.
        • Wiklund F.
        • Klepp O.
        • Angelsen A.
        • Solberg A.
        • Damber J.E.
        • et al.
        Ten- and 15-yr prostate cancer-specific mortality in patients with nonmetastatic locally advanced or aggressive intermediate prostate cancer, randomized to lifelong endocrine treatment alone or combined with radiotherapy: final results of the scandinavian prostate cancer group-7.
        Eur Urol. 2016; 70: 684-691
        • Rusthoven C.G.
        • Carlson J.A.
        • Waxweiler T.V.
        • Raben D.
        • Dewitt P.E.
        • Crawford E.D.
        • et al.
        The impact of definitive local therapy for lymph node-positive prostate cancer: a population-based study.
        Int J Radiat Oncol Biol Phys. 2014; 88: 1064-1073
        • Lin C.C.
        • Gray P.J.
        • Jemal A.
        • Efstathiou J.A.
        Androgen deprivation with or without radiation therapy for clinically node-positive prostate cancer.
        J Natl Cancer Inst. 2015; 107
        • Zagars G.K.
        • Pollack A.
        • von Eschenbach A.C.
        Addition of radiation therapy to androgen ablation improves outcome for subclinically node-positive prostate cancer.
        Urology. 2001; 58: 233-239
        • Tward J.D.
        • Kokeny K.E.
        • Shrieve D.C.
        Radiation therapy for clinically node-positive prostate adenocarcinoma is correlated with improved overall and prostate cancer-specific survival.
        Pract Radiat Oncol. 2013; 3: 234-240
        • James N.D.
        • Spears M.R.
        • Clarke N.W.
        • Dearnaley D.P.
        • Mason M.D.
        • Parker C.C.
        • et al.
        Failure-free survival and radiotherapy in patients with newly diagnosed nonmetastatic prostate cancer: data from patients in the control arm of the STAMPEDE Trial.
        JAMA Oncol. 2016; 2: 348-357
        • Casamassima F.
        • Masi L.
        • Menichelli C.
        • Bonucci I.
        • Casamassima E.
        • Lazzeri M.
        • et al.
        Efficacy of eradicative radiotherapy for limited nodal metastases detected with choline PET scan in prostate cancer patients.
        Tumori. 2011; 97: 49-55
        • Wurschmidt F.
        • Petersen C.
        • Wahl A.
        • Dahle J.
        • Kretschmer M.
        [18F]fluoroethylcholine-PET/CT imaging for radiation treatment planning of recurrent and primary prostate cancer with dose escalation to PET/CT-positive lymph nodes.
        Radiat Oncol. 2011; 6: 44
        • Jereczek-Fossa B.A.
        • Beltramo G.
        • Fariselli L.
        • Fodor C.
        • Santoro L.
        • Vavassori A.
        • et al.
        Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer.
        Int J Radiat Oncol Biol Phys. 2012; 82: 889-897
        • Schick U.
        • Jorcano S.
        • Nouet P.
        • Rouzaud M.
        • Vees H.
        • Zilli T.
        • et al.
        Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastases.
        Acta Oncol. 2013; 52: 1622-1628
        • Decaestecker K.
        • De Meerleer G.
        • Lambert B.
        • Delrue L.
        • Fonteyne V.
        • Claeys T.
        • et al.
        Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence.
        Radiat Oncol. 2014; 9: 135
        • Picchio M.
        • Berardi G.
        • Fodor A.
        • Busnardo E.
        • Crivellaro C.
        • Giovacchini G.
        • et al.
        (11)C-Choline PET/CT as a guide to radiation treatment planning of lymph-node relapses in prostate cancer patients.
        Eur J Nucl Med Mol Imaging. 2014; 41: 1270-1279
        • Detti B.
        • Bonomo P.
        • Masi L.
        • Doro R.
        • Cipressi S.
        • Iermano C.
        • et al.
        Stereotactic radiotherapy for isolated nodal recurrence of prostate cancer.
        World J Urol. 2015; 33: 1197-1203
        • Lepinoy A.
        • Cochet A.
        • Cueff A.
        • Cormier L.
        • Martin E.
        • Maingon P.
        • et al.
        Pattern of occult nodal relapse diagnosed with (18)F-fluoro-choline PET/CT in prostate cancer patients with biochemical failure after prostate-only radiotherapy.
        Radiother Oncol. 2014; 111: 120-125
        • Suardi N.
        • Gandaglia G.
        • Gallina A.
        • Di Trapani E.
        • Scattoni V.
        • Vizziello D.
        • et al.
        Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years.
        Eur Urol. 2015; 67: 299-309
        • Rigatti P.
        • Suardi N.
        • Briganti A.
        • Da Pozzo L.F.
        • Tutolo M.
        • Villa L.
        • et al.
        Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography.
        Eur Urol. 2011; 60: 935-943
        • Ploussard G.
        • Almeras C.
        • Briganti A.
        • Giannarini G.
        • Hennequin C.
        • Ost P.
        • et al.
        Management of node only recurrence after primary local treatment for prostate cancer: a systematic review of the literature.
        J Urol. 2015; 194: 983-988
        • Ost P.
        • Bossi A.
        • Decaestecker K.
        • De Meerleer G.
        • Giannarini G.
        • Karnes R.J.
        • et al.
        Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature.
        Eur Urol. 2015; 67: 852-863
        • Ponti E.
        • Ingrosso G.
        • Carosi A.
        • Di Murro L.
        • Lancia A.
        • Pietrasanta F.
        • et al.
        Salvage stereotactic body radiotherapy for patients with prostate cancer with isolated lymph node metastasis: a single-center experience.
        Clin Genitourin Cancer. 2015; 13: e279-e284
        • Berkovic P.
        • De Meerleer G.
        • Delrue L.
        • Lambert B.
        • Fonteyne V.
        • Lumen N.
        • et al.
        Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy.
        Clin Genitourin Cancer. 2013; 11: 27-32
        • Ost P.
        • Reynders D.
        • Decaestecker K.
        • Fonteyne V.
        • Lumen N.
        • De Bruycker A.
        • et al.
        Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial.
        J Clin Oncol. 2018; 36: 446-453
        • Rischke H.C.
        • Schultze-Seemann W.
        • Wieser G.
        • Kronig M.
        • Drendel V.
        • Stegmaier P.
        • et al.
        Adjuvant radiotherapy after salvage lymph node dissection because of nodal relapse of prostate cancer versus salvage lymph node dissection only.
        Strahlenther Onkol. 2015; 191: 310-320
        • Jilg C.A.
        • Rischke H.C.
        • Reske S.N.
        • Henne K.
        • Grosu A.L.
        • Weber W.
        • et al.
        Salvage lymph node dissection with adjuvant radiotherapy for nodal recurrence of prostate cancer.
        J Urol. 2012; 188: 2190-2197
        • Supiot S.
        • Rio E.
        • Pacteau V.
        • Mauboussin M.H.
        • Campion L.
        • Pein F.
        OLIGOPELVIS – GETUG P07: a multicentre phase II trial of combined salvage radiotherapy and hormone therapy in oligometastatic pelvic node relapses of prostate cancer.
        BMC Cancer. 2015; 15: 646
        • Roach P.J.
        • Francis R.
        • Emmett L.
        • Hsiao E.
        • Kneebone A.
        • Hruby G.
        • et al.
        The impact of 68Ga-PSMA PET/CT on management intent in prostate cancer: results of an Australian prospective multicenter study.
        J Nucl Med. 2018; 59: 82-88
        • Jilg C.A.
        • Drendel V.
        • Rischke H.C.
        • Beck T.
        • Vach W.
        • Schaal K.
        • et al.
        Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-Ligand-PET/CT before Salvage Lymph Node Dissection for Recurrent Prostate Cancer.
        Theranostics. 2017; 7: 1770-1780
        • Siriwardana A.
        • Thompson J.
        • van Leeuwen P.J.
        • Doig S.
        • Kalsbeek A.
        • Emmett L.
        • et al.
        Initial multicentre experience of (68) gallium-PSMA PET/CT guided robot-assisted salvage lymphadenectomy: acceptable safety profile but oncological benefit appears limited.
        BJU Int. 2017; 120: 673-681
        • Kneebone A.H.G.
        • Ainsworth H.
        • Byrne K.
        • Brown C.
        • Guo L.
        • et al.
        Stereotactic body radiotherapy for oligometastatic prostate cancer detected via prostate-specific membrane antigen positron emission tomography.
        Eur Urol Oncol. 2018; (in press)https://doi.org/10.1016/j. euo.2018.04.017
        • Lawton C.A.
        • Michalski J.
        • El-Naqa I.
        • Buyyounouski M.K.
        • Lee W.R.
        • Menard C.
        • et al.
        RTOG GU Radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer.
        Int J Radiat Oncol Biol Phys. 2009; 74: 383-387
        • Harris V.A.
        • Staffurth J.
        • Naismith O.
        • Esmail A.
        • Gulliford S.
        • Khoo V.
        • et al.
        Consensus guidelines and contouring atlas for pelvic node delineation in prostate and pelvic node intensity modulated radiation therapy.
        Int J Radiat Oncol Biol Phys. 2015; 92: 874-883
        • Parker W.P.
        • Evans J.D.
        • Stish B.J.
        • Park S.S.
        • Olivier K.
        • Choo R.
        • et al.
        Patterns of recurrence after postprostatectomy fossa radiation therapy identified by C-11 choline positron emission tomography/computed tomography.
        Int J Radiat Oncol Biol Phys. 2017; 97: 526-535
        • Warde P.
        • Mason M.
        • Ding K.
        • Kirkbride P.
        • Brundage M.
        • Cowan R.
        • et al.
        Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.
        Lancet. 2011; 378: 2104-2111
        • Mason M.D.
        • Parulekar W.R.
        • Sydes M.R.
        • Brundage M.
        • Kirkbride P.
        • Gospodarowicz M.
        • et al.
        Final report of the intergroup randomized study of combined androgen-deprivation therapy plus radiotherapy versus androgen-deprivation therapy alone in locally advanced prostate cancer.
        J Clin Oncol. 2015; 33: 2143-2150
        • Bolla M.
        • Collette L.
        • Blank L.
        • Warde P.
        • Dubois J.B.
        • Mirimanoff R.O.
        • et al.
        Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial.
        Lancet. 2002; 360: 103-106
        • Pilepich M.V.
        • Winter K.
        • Lawton C.A.
        • Krisch R.E.
        • Wolkov H.B.
        • Movsas B.
        • et al.
        Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma–long-term results of phase III RTOG 85–31.
        Int J Radiat Oncol Biol Phys. 2005; 61: 1285-1290
        • Roach 3rd, M.
        • DeSilvio M.
        • Lawton C.
        • Uhl V.
        • Machtay M.
        • Seider M.J.
        • et al.
        Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413.
        J Clin Oncol. 2003; 21: 1904-1911
        • Lawton C.A.
        • DeSilvio M.
        • Roach 3rd, M.
        • Uhl V.
        • Kirsch R.
        • Seider M.
        • et al.
        An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions.
        Int J Radiat Oncol Biol Phys. 2007; 69: 646-655
        • Pommier P.
        • Chabaud S.
        • Lagrange J.L.
        • Richaud P.
        • Le Prise E.
        • Wagner J.P.
        • et al.
        Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Update of the long-term survival results of the GETUG-01 randomized study.
        Int J Radiat Oncol Biol Phys. 2016; 96: 759-769
        • Pommier P.
        • Chabaud S.
        • Lagrange J.L.
        • Richaud P.
        • Lesaunier F.
        • Le Prise E.
        • et al.
        Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01.
        J Clin Oncol. 2007; 25: 5366-5373
        • Adkison J.B.
        • McHaffie D.R.
        • Bentzen S.M.
        • Patel R.R.
        • Khuntia D.
        • Petereit D.G.
        • et al.
        Phase I trial of pelvic nodal dose escalation with hypofractionated IMRT for high-risk prostate cancer.
        Int J Radiat Oncol Biol Phys. 2012; 82: 184-190
        • Engels B.
        • Soete G.
        • Tournel K.
        • Bral S.
        • De Coninck P.
        • Verellen D.
        • et al.
        Helical tomotherapy with simultaneous integrated boost for high-risk and lymph node-positive prostate cancer: early report on acute and late toxicity.
        Technol Cancer Res Treat. 2009; 8: 353-359
        • Loblaw D.A.
        • Virgo K.S.
        • Nam R.
        • Somerfield M.R.
        • Ben-Josef E.
        • Mendelson D.S.
        • et al.
        Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline.
        J Clin Oncol. 2007; 25: 1596-1605
        • Sze W.M.
        • Shelley M.
        • Held I.
        • Mason M.
        Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy – a systematic review of the randomised trials.
        Cochrane Database Syst Rev. 2004; : CD004721
        • Correa R.J.
        • Salama J.K.
        • Milano M.T.
        • Palma D.A.
        Stereotactic body radiotherapy for oligometastasis: opportunities for biology to guide clinical management.
        Cancer J. 2016; 22: 247-256
        • Gundem G.
        • Van Loo P.
        • Kremeyer B.
        • Alexandrov L.B.
        • Tubio J.M.C.
        • Papaemmanuil E.
        • et al.
        The evolutionary history of lethal metastatic prostate cancer.
        Nature. 2015; 520: 353-357
        • de Jong M.C.
        • Pulitano C.
        • Ribero D.
        • Strub J.
        • Mentha G.
        • Schulick R.D.
        • et al.
        Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients.
        Ann Surg. 2009; 250: 440-448
        • Hofmann H.S.
        • Neef H.
        • Krohe K.
        • Andreev P.
        • Silber R.E.
        Prognostic factors and survival after pulmonary resection of metastatic renal cell carcinoma.
        Eur Urol. 2005; 48 (discussion 81-2): 77-81
        • Pfannschmidt J.
        • Hoffmann H.
        • Muley T.
        • Krysa S.
        • Trainer C.
        • Dienemann H.
        Prognostic factors for survival after pulmonary resection of metastatic renal cell carcinoma.
        Ann Thorac Surg. 2002; 74: 1653-1657
        • Ost P.
        • Jereczek-Fossa B.A.
        • As N.V.
        • Zilli T.
        • Muacevic A.
        • Olivier K.
        • et al.
        Progression-free survival following stereotactic body radiotherapy for oligometastatic prostate cancer treatment-naive recurrence: a multi-institutional analysis.
        Eur Urol. 2016; 69: 9-12
        • Siva S.U.C.
        • Shaw M.
        • Violet J.
        • Chander S.
        • Bressel M.
        • Goad J.
        • et al.
        Stereotacic radiotherapy for bone and nodal oligometastases: Patterns of relapse in a prospective clinical trial.
        Eur Urol. 2017; 16e1675
        • Radwan N.
        • Phillips R.
        • Ross A.
        • Rowe S.P.
        • Gorin M.A.
        • Antonarakis E.S.
        • et al.
        A phase II randomized trial of observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE).
        BMC Cancer. 2017; 17: 453
        • Roach 3rd, M.
        • Hanks G.
        • Thames Jr., H.
        • Schellhammer P.
        • Shipley W.U.
        • Sokol G.H.
        • et al.
        Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference.
        Int J Radiat Oncol Biol Phys. 2006; 65: 965-974
        • Bolla M.
        • Van Tienhoven G.
        • Warde P.
        • Dubois J.B.
        • Mirimanoff R.O.
        • Storme G.
        • et al.
        External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study.
        Lancet Oncol. 2010; 11: 1066-1073
        • Kuban D.A.
        • Thames H.D.
        • Levy L.B.
        • Horwitz E.M.
        • Kupelian P.A.
        • Martinez A.A.
        • et al.
        Long-term multi-institutional analysis of stage T1–T2 prostate cancer treated with radiotherapy in the PSA era.
        Int J Radiat Oncol Biol Phys. 2003; 57: 915-928
        • Abd-Alazeez M.
        • Ramachandran N.
        • Dikaios N.
        • Ahmed H.U.
        • Emberton M.
        • Kirkham A.
        • et al.
        Multiparametric MRI for detection of radiorecurrent prostate cancer: added value of apparent diffusion coefficient maps and dynamic contrast-enhanced images.
        Prostate Cancer Prostatic Dis. 2015; 18: 128-136
        • Rud E.
        • Baco E.
        • Lien D.
        • Klotz D.
        • Eggesbo H.B.
        Detection of radiorecurrent prostate cancer using diffusion-weighted imaging and targeted biopsies.
        AJR Am J Roentgenol. 2014; 202: W241-W246
        • Kara T.
        • Akata D.
        • Akyol F.
        • Karcaaltincaba M.
        • Ozmen M.
        The value of dynamic contrast-enhanced MRI in the detection of recurrent prostate cancer after external beam radiotherapy: correlation with transrectal ultrasound and pathological findings.
        Diagn Interv Radiol. 2011; 17: 38-43
        • Arumainayagam N.
        • Kumaar S.
        • Ahmed H.U.
        • Moore C.M.
        • Payne H.
        • Freeman A.
        • et al.
        Accuracy of multiparametric magnetic resonance imaging in detecting recurrent prostate cancer after radiotherapy.
        BJU Int. 2010; 106: 991-997
        • Rouviere O.
        • Valette O.
        • Grivolat S.
        • Colin-Pangaud C.
        • Bouvier R.
        • Chapelon J.Y.
        • et al.
        Recurrent prostate cancer after external beam radiotherapy: value of contrast-enhanced dynamic MRI in localizing intraprostatic tumor–correlation with biopsy findings.
        Urology. 2004; 63: 922-927
        • Alongi F.
        • De Bari B.
        • Campostrini F.
        • Arcangeli S.
        • Matei D.V.
        • Lopci E.
        • et al.
        Salvage therapy of intraprostatic failure after radical external-beam radiotherapy for prostate cancer: a review.
        Crit Rev Oncol Hematol. 2013; 88: 550-563
        • Hruby G.
        • Eade T.
        • Kneebone A.
        • Emmett L.
        • Guo L.
        • Ho B.
        • et al.
        Delineating biochemical failure with 68Ga-PSMA-PET following definitive external beam radiation treatment for prostate cancer.
        Radiother Oncol. 2017; 122: 99-102
        • Crook J.
        • Malone S.
        • Perry G.
        • Bahadur Y.
        • Robertson S.
        • Abdolell M.
        Postradiotherapy prostate biopsies: what do they really mean? Results for 498 patients.
        Int J Radiat Oncol Biol Phys. 2000; 48: 355-367
        • Cox J.D.
        • Gallagher M.J.
        • Hammond E.H.
        • Kaplan R.S.
        • Schellhammer P.F.
        Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel.
        J Clin Oncol. 1999; 17: 1155
        • Duchesne G.M.
        • Woo H.H.
        • Bassett J.K.
        • Bowe S.J.
        • D'Este C.
        • Frydenberg M.
        • et al.
        Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01–03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial.
        Lancet Oncol. 2016; 17: 727-737
        • Duijzentkunst D.A.
        • Peters M.
        • van der Voort van Zyp J.R.
        • Moerland M.A.
        • van Vulpen M.
        Focal salvage therapy for local prostate cancer recurrences after primary radiotherapy: a comprehensive review.
        World J Urol. 2016; 34: 1521-1531
        • Scheltema M.J.
        • van den Bos W.
        • Siriwardana A.R.
        • Kalsbeek A.M.F.
        • Thompson J.E.
        • Ting F.
        • et al.
        Feasibility and safety of focal irreversible electroporation as salvage treatment for localized radio-recurrent prostate cancer.
        BJU Int. 2017; 120: 51-58
        • Chade D.C.
        • Eastham J.
        • Graefen M.
        • Hu J.C.
        • Karnes R.J.
        • Klotz L.
        • et al.
        Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: a systematic review of the literature.
        Eur Urol. 2012; 61: 961-971
        • Bianco Jr., F.J.
        • Scardino P.T.
        • Stephenson A.J.
        • Diblasio C.J.
        • Fearn P.A.
        • Eastham J.A.
        Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy.
        Int J Radiat Oncol Biol Phys. 2005; 62: 448-453
        • Ward J.F.
        • Sebo T.J.
        • Blute M.L.
        • Zincke H.
        Salvage surgery for radiorecurrent prostate cancer: contemporary outcomes.
        J Urol. 2005; 173: 1156-1160
        • Chade D.C.
        • Shariat S.F.
        • Cronin A.M.
        • Savage C.J.
        • Karnes R.J.
        • Blute M.L.
        • et al.
        Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration.
        Eur Urol. 2011; 60: 205-210
        • Rosoff J.S.
        • Savage S.J.
        • Prasad S.M.
        Salvage radical prostatectomy as management of locally recurrent prostate cancer: outcomes and complications.
        World J Urol. 2013; 31: 1347-1352
        • Nguyen P.L.
        • D'Amico A.V.
        • Lee A.K.
        • Suh W.W.
        Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: a systematic review of the literature.
        Cancer. 2007; 110: 1417-1428
        • Tetreault-Laflamme A.
        • Crook J.
        Options for Salvage of Radiation Failures for Prostate Cancer.
        Semin Radiat Oncol. 2017; 27: 67-78

      Linked Article

      • Imaging and radiotherapy for recurrent prostate cancer: An evolutionary partnership
        Radiotherapy and OncologyVol. 129Issue 2
        • Preview
          We applaud the Australian and New Zealand Radiation Oncology Genito-Urinary Group for their exemplary review and recommendations of management for prostate cancer patients with recurrence [1]. Technological advances in imaging and radiotherapy have enabled ‘new’ disease states to be recognized and managed, however, these need to be robustly evaluated to ensure clinically appropriate endpoints are met before introducing into routine clinical care.
        • Full-Text
        • PDF